Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
The product is expected to be launched in December 2023
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Subscribe To Our Newsletter & Stay Updated
